Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat

被引:92
作者
Reimsnider, Sharon
Manfredsson, Fredric P.
Muzyczka, Nicholas
Mandel, Ronald J.
机构
[1] Univ Florida, Coll Med, Dept Neurosci, Powell Gene Therapy Ctr,McKnight Brain Inst, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Powell Gene Therapy Ctr,McKnight Brain Inst, Gainesville, FL 32610 USA
关键词
D O I
10.1038/sj.mt.6300227
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In vivo recombinant adeno-associated viral vector (rAAV)-mediated transduction of various tissues including brain has been characterized by slow onset and gradual increase in gene expression before reaching stable long-term protein levels. The early time course of transgene expression has not been quantified using newly available rAAV capsid serotypes. In this experiment, the onset of expression of green fluorescent protein (GFP) after intrastriatal injection of rAAV2-based pseudotyped vectors (rAAV1, rAAV5, and rAAV8 capsids) was quantified. Native GFP fluorescence displayed a delayed onset of expression of at least 7 days for all the pseudotyped rAAV vectors. However, GFP immunohistochemical staining revealed significant transgene expression by 4 days after transduction for all serotypes and stable GFP(+) neuronal populations mediated by all serotypes within 14 days post transduction at the latest. rAAV2/1 and rAAV2/2 displayed no time-dependent increase of GFP(+) striatal neurons; reaching maximal striatal cell GFP(+) counts at 4 days after injection. All serotypes displayed peak transgene expression by 4 weeks post injection where native GFP(+) neurons were equal to immunostained striatal GFP(+) neurons. The inflammatory response to these rAAV vectors was present up to 4 weeks after transduction but was not apparent 9 months post injection. Thus, rAAV-mediated transgene expression begins earlier than previously thought.
引用
收藏
页码:1504 / 1511
页数:8
相关论文
共 44 条
[1]   Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[2]   Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion [J].
Burger, C ;
Nguyen, FN ;
Deng, J ;
Mandel, RJ .
MOLECULAR THERAPY, 2005, 11 (02) :327-331
[3]   Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system [J].
Burger, C ;
Gorbatyuk, OS ;
Velardo, MJ ;
Peden, CS ;
Williams, P ;
Zolotukhin, S ;
Reier, PJ ;
Mandel, RJ ;
Muzyczka, N .
MOLECULAR THERAPY, 2004, 10 (02) :302-317
[4]   Recombinant adeno-associated viral vectors in the nervous system [J].
Burger, C ;
Nash, K ;
Mandel, RJ .
HUMAN GENE THERAPY, 2005, 16 (07) :781-791
[5]   Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system [J].
Davidson, BL ;
Stein, CS ;
Heth, JA ;
Martins, I ;
Kotin, RM ;
Derksen, TA ;
Zabner, J ;
Ghodsi, A ;
Chiorini, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3428-3432
[6]   Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia [J].
Ding, W ;
Yan, ZY ;
Zak, R ;
Saavedra, M ;
Rodman, DM ;
Engelhardt, JF .
JOURNAL OF VIROLOGY, 2003, 77 (13) :7361-7366
[7]   Intracellular trafficking of adeno-associated viral vectors [J].
Ding, W ;
Zhang, L ;
Yan, Z ;
Engelhardt, JF .
GENE THERAPY, 2005, 12 (11) :873-880
[8]  
Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt
[9]  
406::AID-JMV22&gt
[10]  
3.0.CO